RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: CEA A01
Target: Homo sapien - CEA
Type of nucleic acid: ssRNA
Sequence: 5'AUCGUUACCUUAGAAGCUUAGGCACGACGCAUAGCCUUGGGAGCGAGGAGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3'
Sequence length: 82
GC content: 0.5121951219512195
Affinity: Kd: 16.5 nM
Pool type: 5'-ATCGTTACCTTAGAAGCTT-N30-GGATCCGACACGACCCTATAGTGAGTCGTATTA-3'
Pool random region: 30
Binding buffer/conditions: BSA 1mg/ml in Dulbecco's PBS without calcium and magnesium (pH 7.3), Mg2Cl 5mM, glucose 4.5g/L, Salmon Sperm DNA 0.1 mg/ml and yeast tRNA 0.1 mg/ml
Buffer type: PBS/phosphate buffers
pH: 7.3
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpaeutic: " these novel RNA aptamers targeting gastrointestinal cancer biomarker CEA, CA50 and CA72-4 will aid further development and standardization of clinical diagnostic method with better sensitivity and specificity, and potentially future therapeutics development of gastric cancer. It is possible that such aptamers would become applicable in clinical applications or even therapeutics in the near future with better sensitivity and specificity, and without the limitations of immunoassays."
Reference (2018, PLoS One ): Pan, Q., Law, C. O. K., Yung, M. M. H., Han, K. C., Pon, Y. L., & Lau, T. C. K. (2018). Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity. PloS one, 13(10), e0198980. https://doi.org/10.1371/journal.pone.0198980
Aptamer: CA72-4 A01
Target: Homo sapien - CA72-4
Type of nucleic acid: ssRNA
Sequence: 5'AUCGUUACCUUAGAAGCUUUGCGAAGGGGGGCAGAGGUUUGACGCGAGAGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3'
Sequence length: 82
GC content: 0.5121951219512195
Affinity: Kd: 52.7 nM
Pool type: 5'-ATCGTTACCTTAGAAGCTT-N30-GGATCCGACACGACCCTATAGTGAGTCGTATTA-3'
Pool random region: 30
Binding buffer/conditions: BSA 1mg/ml in Dulbecco's PBS without calcium and magnesium (pH 7.3), Mg2Cl 5mM, glucose 4.5g/L, Salmon Sperm DNA 0.1 mg/ml and yeast tRNA 0.1 mg/ml
Buffer type: PBS/phosphate buffers
pH: 7.3
Molecular weight of target: 220 - 400 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpaeutic: " these novel RNA aptamers targeting gastrointestinal cancer biomarker CEA, CA50 and CA72-4 will aid further development and standardization of clinical diagnostic method with better sensitivity and specificity, and potentially future therapeutics development of gastric cancer. It is possible that such aptamers would become applicable in clinical applications or even therapeutics in the near future with better sensitivity and specificity, and without the limitations of immunoassays."
Reference (2018, PLoS One ): Pan, Q., Law, C. O. K., Yung, M. M. H., Han, K. C., Pon, Y. L., & Lau, T. C. K. (2018). Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity. PloS one, 13(10), e0198980. https://doi.org/10.1371/journal.pone.0198980
Aptamer: CA50 A02
Target: Homo sapien - CA50
Type of nucleic acid: ssRNA
Sequence: 5'AUCGUUACCUUAGAAGCUUAGCUCGAAAGUGGGCUGGCGAUGUGUCCCGGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3'
Sequence length: 82
GC content: 0.5121951219512195
Affinity: Kd: 30.7 nM
Pool type: 5'-ATCGTTACCTTAGAAGCTT-N30-GGATCCGACACGACCCTATAGTGAGTCGTATTA-3'
Pool random region: 30
Binding buffer/conditions: BSA 1mg/ml in Dulbecco's PBS without calcium and magnesium (pH 7.3), Mg2Cl 5mM, glucose 4.5g/L, Salmon Sperm DNA 0.1 mg/ml and yeast tRNA 0.1 mg/ml
Buffer type: PBS/phosphate buffers
pH: 7.3
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpaeutic: " these novel RNA aptamers targeting gastrointestinal cancer biomarker CEA, CA50 and CA72-4 will aid further development and standardization of clinical diagnostic method with better sensitivity and specificity, and potentially future therapeutics development of gastric cancer. It is possible that such aptamers would become applicable in clinical applications or even therapeutics in the near future with better sensitivity and specificity, and without the limitations of immunoassays."
Reference (2018, PLoS One ): Pan, Q., Law, C. O. K., Yung, M. M. H., Han, K. C., Pon, Y. L., & Lau, T. C. K. (2018). Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity. PloS one, 13(10), e0198980. https://doi.org/10.1371/journal.pone.0198980
Aptamer: F5R1
Target: Alpha-synuclein (α-syn) with Glutathione S-transferase (GST) tag
Type of nucleic acid: ssDNA
Sequence: 5'ATCGAGTGTGTACGGGGTCCGGTAGGGTGGCGAGGTCTTCCTGTCGTAGCAGGATCCA3'
Sequence length: 58
GC content: 0.603448275862069
Affinity: Kd: 2.40 nM
Pool type: 5′-GATGTGGTAGGTGATCGAGTG-N58-GCAGGATCCATCCACCTCTA-3′
Pool random region: 40
Binding buffer/conditions: 10 mM Tris-HCI, 1 mM EDTA, 2 M NaCI, pH7.5
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Aptamers against the protein of α-syn inhibited α-syn aggregation and further targeted the cellular α-syn to degradation through the lysosomal pathway, consequently rescuing the mitochondrial dysfunction and cell defects in the α-syn overexpressing SK-N-SH cells and primary neurons. With future experiments in animals, these aptamers could be developed as a unique and potential strategy to target α-syn in the context of Parkinsons therapy."
Reference (2018, Mol Ther Nucleic Acids ): Zheng, Y., Qu, J., Xue, F., Zheng, Y., Yang, B., Chang, Y., Yang, H., & Zhang, J. (2018). Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation. Molecular therapy. Nucleic acids, 11, 228–242. https://doi.org/10.1016/j.omtn.2018.02.011
Aptamer: F5R2
Target: Alpha-synuclein (α-syn) with Glutathione S-transferase (GST) tag
Type of nucleic acid: ssDNA
Sequence: 5'ATCGAGTGGACGAGTGCCTCCGGTACGAGCTGTCTGATGGGTTTGCGCGCAGGATCCA3'
Sequence length: 58
GC content: 0.603448275862069
Affinity: Kd: 3.07 nM
Pool type: 5′-GATGTGGTAGGTGATCGAGTG-N40-GCAGGATCCATCCACCTCTA-3′
Pool random region: 40
Binding buffer/conditions: 10 mM Tris-HCI, 1 mM EDTA, 2 M NaCI, pH7.5
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The majority of the primer binding regions were removed from the aptamer sequences: 8 bases from the initial primer binding region and 10 bases from the ending primer binding region were synthesized along with the middle 40 random region to yield a 58-base aptamer.
Application as quoted in the referenced paper: Therapeutic: " Aptamers against the protein of α-syn inhibited α-syn aggregation and further targeted the cellular α-syn to degradation through the lysosomal pathway, consequently rescuing the mitochondrial dysfunction and cell defects in the α-syn overexpressing SK-N-SH cells and primary neurons. With future experiments in animals, these aptamers could be developed as a unique and potential strategy to target α-syn in the context of Parkinsons therapy."
Reference (2018, Mol Ther Nucleic Acids ): Zheng, Y., Qu, J., Xue, F., Zheng, Y., Yang, B., Chang, Y., Yang, H., & Zhang, J. (2018). Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation. Molecular therapy. Nucleic acids, 11, 228–242. https://doi.org/10.1016/j.omtn.2018.02.011
Aptamer: ApTLR#1R
Target: Recombinant Human TLR4
Type of nucleic acid: ssDNA
Sequence: 5'GTTGCTCGTTATTTAGGGCCACCGGCACGGGACAAGGCGCGGGACGGCGTAGATCAGGTCGACACCAGTCTTCATCCGC3'
Sequence length: 79
GC content: 0.620253164556962
Affinity: Not reported
Pool type: 5′-GCGGATGAAGACTGGTGT-N40-GCCCTAAATACGAGCAAC-3′
Pool random region: 40
Binding buffer/conditions: 20 mM Tris-HCl [pH 7.4]; 150 mM NaCl; 1 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 70.1 Kda
Application as quoted in the referenced paper: Therapeutic: " Efficacy of ApTLR#4FT in a model of brain ischemia-reperfusion in rat supports the use of this aptamer in patients undergoing artery recanalization induced by pharmacological or mechanical interventions. Aptamers capable to specifically bind and regulate TLR4 function have the potential to be effective inhibitors of TLR4-mediated signaling in vitro and in vivo, offering an effective and safe alternative treatment option for stroke and other diseases in which TLR4 plays an ethiopathogenic role."
Reference (2018, Mol Ther ): Fernández, G., Moraga, A., Cuartero, M. I., García-Culebras, A., Peña-Martínez, C., Pradillo, J. M., Hernández-Jiménez, M., Sacristán, S., Ayuso, M. I., Gonzalo-Gobernado, R., Fernández-López, D., Martín, M. E., Moro, M. A., González, V. M., & Lizasoain, I. (2018). TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models. Molecular therapy : the journal of the American Society of Gene Therapy, 26(8), 2047–2059. https://doi.org/10.1016/j.ymthe.2018.05.019
Aptamer: ApTLR#4F
Target: Recombinant Human TLR4
Type of nucleic acid: ssDNA
Sequence: 5'GCGGATGAAGACTGGTGTGCCAATAAACCATATCGCCGCGTTAGCATGTACTCGGTTGGCCCTAAATACGAGCAAC3'
Sequence length: 76
GC content: 0.5131578947368421
Affinity: Not reported
Pool type: 5′-GCGGATGAAGACTGGTGT-N40-GCCCTAAATACGAGCAAC-3′
Pool random region: 40
Binding buffer/conditions: 20 mM Tris-HCl [pH 7.4]; 150 mM NaCl; 1 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 70.1 Kda
Application as quoted in the referenced paper: Therapeutic: " Efficacy of ApTLR#4FT in a model of brain ischemia-reperfusion in rat supports the use of this aptamer in patients undergoing artery recanalization induced by pharmacological or mechanical interventions. Aptamers capable to specifically bind and regulate TLR4 function have the potential to be effective inhibitors of TLR4-mediated signaling in vitro and in vivo, offering an effective and safe alternative treatment option for stroke and other diseases in which TLR4 plays an ethiopathogenic role."
Reference (2018, Mol Ther ): Fernández, G., Moraga, A., Cuartero, M. I., García-Culebras, A., Peña-Martínez, C., Pradillo, J. M., Hernández-Jiménez, M., Sacristán, S., Ayuso, M. I., Gonzalo-Gobernado, R., Fernández-López, D., Martín, M. E., Moro, M. A., González, V. M., & Lizasoain, I. (2018). TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models. Molecular therapy : the journal of the American Society of Gene Therapy, 26(8), 2047–2059. https://doi.org/10.1016/j.ymthe.2018.05.019
Aptamer: M17
Target: Membrane proteins of matrix metalloproteinase 14 (MMP14) transfected 293T cells
Type of nucleic acid: ssDNA
Sequence: 5'TGCGGAAGCCACCAGGAGTTAGGGCCCGACGTGACGGCACGTCGGATATCTCATGCGTGTACGAGCCAAAGAGCCGCCAA3'
Sequence length: 80
GC content: 0.6125
Affinity: Kd: 4.98±1.26 nM
Pool type: 5′-TGCGGAAGCCACCAGGAGTT-40N-ACGAGCCAAAGAGCCGCCAA-3′
Pool random region: 40
Binding buffer/conditions: PBS containing 10% FCS and 0.02% NaN3
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " MMP14 was highly expressed in the pancreatic cancer group, while the surrounding pancreatic tissue had a low expression level. Therefore, MMP14 has great application prospects as a tumor biomarker. Previously, there have been a number of reports of MMP14-specific functional blocking antibodies and nanosensors, which indicate MMP14 may be a useful tool for diagnostic and therapeutic applications."
Reference (2019, Oncol Lett ): Huang, X., Zhong, J., Ren, J., Wen, D., Zhao, W., & Huan, Y. (2019). A DNA aptamer recognizing MMP14 for in vivo and in vitro imaging identified by cell-SELEX. Oncology letters, 18(1), 265–274. https://doi.org/10.3892/ol.2019.10282
Aptamer: NA36
Target: Neutrophil gelatinase-associated lipocalin (NGAL)
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGCACAGAGGTCAGATGCCCATATGCTACTTTGCACACATCCTGGATAGGCTCCTATGCGTGCTACCGTGAA3'
Sequence length: 75
GC content: 0.52
Affinity: Kd: 43.59 nM
Pool type: 5'-AGCAGCACAGAGGTCAGATG-N35-CCTATGCGTGCTACCGTGAA-3'
Pool random region: 35
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagonistic: " NGAL is closely correlated with the acute kidney injury (AKI) severity, and thus it may be served as a powerful indicator in clinical application. The binding of aptamer NA53 to NGAL protein in urine was also validated after performance verification. More importantly, no cross-reactions occurred between aptamer NA53 and other main components in urine including albumin and globulin after test with ELAA method, thus the ELAA method in our study is worth popularizing for NGAL protein test."
Reference (2019, J Transl Med ): Hong, X., Yan, H., Xie, F., Wang, K., Wang, Q., Huang, H., Yang, K., Huang, S., Zhao, T., Wang, J., Chen, Y., Liu, K., & Lan, X. (2019). Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials. Journal of translational medicine, 17(1), 204. https://doi.org/10.1186/s12967-019-1955-7
Aptamer: NA42
Target: Neutrophil gelatinase-associated lipocalin (NGAL)
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGCACAGAGGTCAGATGCCGTGCGGATGTACAGGGACTTGGATAGTTTCTGACCTATGCGTGCTACCGTGAA3'
Sequence length: 75
GC content: 0.5333333333333333
Affinity: Kd: 66.55 nM
Pool type: 5'-AGCAGCACAGAGGTCAGATG-N35-CCTATGCGTGCTACCGTGAA-3'
Pool random region: 35
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagonistic: " NGAL is closely correlated with the acute kidney injury (AKI) severity, and thus it may be served as a powerful indicator in clinical application. The binding of aptamer NA53 to NGAL protein in urine was also validated after performance verification. More importantly, no cross-reactions occurred between aptamer NA53 and other main components in urine including albumin and globulin after test with ELAA method, thus the ELAA method in our study is worth popularizing for NGAL protein test."
Reference (2019, J Transl Med ): Hong, X., Yan, H., Xie, F., Wang, K., Wang, Q., Huang, H., Yang, K., Huang, S., Zhao, T., Wang, J., Chen, Y., Liu, K., & Lan, X. (2019). Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials. Journal of translational medicine, 17(1), 204. https://doi.org/10.1186/s12967-019-1955-7
Aptamer: NA53
Target: Neutrophil gelatinase-associated lipocalin (NGAL)
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGCACAGAGGTCAGATGGCGCTGGATAGCAAGATCACGTTATCATCGTAAACCCTATGCGTGCTACCGTGAA3'
Sequence length: 75
GC content: 0.5066666666666667
Affinity: Kd: 32.52 nM
Pool type: 5'-AGCAGCACAGAGGTCAGATG-N35-CCTATGCGTGCTACCGTGAA-3'
Pool random region: 35
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagonistic: " NGAL is closely correlated with the acute kidney injury (AKI) severity, and thus it may be served as a powerful indicator in clinical application. The binding of aptamer NA53 to NGAL protein in urine was also validated after performance verification. More importantly, no cross-reactions occurred between aptamer NA53 and other main components in urine including albumin and globulin after test with ELAA method, thus the ELAA method in our study is worth popularizing for NGAL protein test."
Reference (2019, J Transl Med ): Hong, X., Yan, H., Xie, F., Wang, K., Wang, Q., Huang, H., Yang, K., Huang, S., Zhao, T., Wang, J., Chen, Y., Liu, K., & Lan, X. (2019). Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials. Journal of translational medicine, 17(1), 204. https://doi.org/10.1186/s12967-019-1955-7
Aptamer: BI-1
Target: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1)
Type of nucleic acid: ssDNA
Sequence: 5'AGCGATACTGCGTGGCTGGAGGCGGGTAGGGCCAGAGTTC3'
Sequence length: 40
GC content: 0.65
Affinity: Not reported
Pool type: 5′-ATCCAGAGTGACGCAGCA-N40-TGGACACGGTGGCTTAGT-3′
Pool random region: 40
Binding buffer/conditions: 4.5 g glucose, 100 mg tRNA, 50 mg of salmon sperm DNA, 1 g BSA, and 5 mL of 1 M MgCl21 in 1 L of Dulbecco's phosphate buffered saline [DPBS]
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Cholesteryl tetraetylene glycol (teg) improved the potency of aptamer
Application as quoted in the referenced paper: Therapeutic: " The DNA aptamer optimized to target BACE1 under physiological status has an inhibitory effect on BACE1 activity and Aβ production, and its protective effect on Aβ-induced neuronal deficiency, are validated in various in vitro and cellular assays. The potential of BACE1-targeting aptamer as an intervention for AD deserves further investigation.target BACE1 in Alzheimer paitients."
Additional information: Two primers were used for PCR amplification: fluorescein (FAM)-labeled forward primer (5′-FAM-AAG GAG CAG CGT GGA GGA TA-3′) and biotin-labeled reverse primer (5′-biotin-ACC ACG ACG ACA CAC CCT AA-3′).
Reference (2019, Mol Ther Nucleic Acids ): Xiang, J., Zhang, W., Cai, X. F., Cai, M., Yu, Z. H., Yang, F., Zhu, W., Li, X. T., Wu, T., Zhang, J. S., & Cai, D. F. (2019). DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells. Molecular therapy. Nucleic acids, 16, 302–312. https://doi.org/10.1016/j.omtn.2019.02.025
Aptamer: BI-2
Target: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1)
Type of nucleic acid: ssDNA
Sequence: 5′ATCCAGAGTGACGCAGCATTTTATCAGGGCTACAGAGGTCAGAGTTACTTAGAGCAGGTGGACACGGTGGCTTAGT3′
Sequence length: 76
GC content: 0.5
Affinity: Not reported
Pool type: 5′-ATCCAGAGTGACGCAGCA-N40-TGGACACGGTGGCTTAGT-3′
Pool random region: 40
Binding buffer/conditions: 4.5 g glucose, 100 mg tRNA, 50 mg of salmon sperm DNA, 1 g BSA, and 5 mL of 1 M MgCl21 in 1 L of Dulbecco's phosphate buffered saline [DPBS]
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Cholesteryl tetraetylene glycol (teg) improved the potency of aptamer
Application as quoted in the referenced paper: Therapeutic: " The DNA aptamer optimized to target BACE1 under physiological status has an inhibitory effect on BACE1 activity and Aβ production, and its protective effect on Aβ-induced neuronal deficiency, are validated in various in vitro and cellular assays. The potential of BACE1-targeting aptamer as an intervention for AD deserves further investigation.target BACE1 in Alzheimer paitients."
Additional information: Two primers were used for PCR amplification: fluorescein (FAM)-labeled forward primer (5′-FAM-AAG GAG CAG CGT GGA GGA TA-3′) and biotin-labeled reverse primer (5′-biotin-ACC ACG ACG ACA CAC CCT AA-3′).
Reference (2019, Mol Ther Nucleic Acids ): Xiang, J., Zhang, W., Cai, X. F., Cai, M., Yu, Z. H., Yang, F., Zhu, W., Li, X. T., Wu, T., Zhang, J. S., & Cai, D. F. (2019). DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells. Molecular therapy. Nucleic acids, 16, 302–312. https://doi.org/10.1016/j.omtn.2019.02.025
Aptamer: cTX-24
Target: Ovarian cancer tissues (OVCAR-3, National Cancer Institute #0507709, 104 cells per test)
Type of nucleic acid: ssDNA
Sequence: 5'GGCAGGAAGACAAACACCCCCCCGGTTCCATCCCGTCATGATTTTCCGTAATTTGATGGTCTGTGGTGCTGT3'
Sequence length: 72
GC content: 0.5277777777777778
Affinity: Kd: 1348 ± 518.1 nM
Pool type: 5′-GGCAGGAAGACAAACA-N40-TGGTCTGTGGTGCTGT-3′
Pool random region: 40
Binding buffer/conditions: 50 ml of Dulbecco's phosphate-buffered saline (DPBS; Sigma, USA), 0.225 g of glucose, 250 μl of 1 M MgCl2, and 5 mg of yeast transfer RNA (tRNA; Invitrogen, USA)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Given the comparable specificity to their much more expensive antibody counterparts, these aptamers, when used in conjunction with the developed microfluidic system, may be used to diagnose ovarian cancer in its earliest stages. Automated, microfluidic, tissue-SELEX system developed herein is a promising tool for rapid screening cancer tissue-specific aptamers."
Reference (2019, Biomicrofluidics ): Liu, W. T., Lee, W. B., Tsai, Y. C., Chuang, Y. J., Hsu, K. F., & Lee, G. B. (2019). An automated microfluidic system for selection of aptamer probes against ovarian cancer tissues. Biomicrofluidics, 13(1), 014114. https://doi.org/10.1063/1.5085133
Aptamer: cTX-36
Target: Ovarian cancer tissues (OVCAR-3, National Cancer Institute #0507709, 104 cells per test)
Type of nucleic acid: ssDNA
Sequence: 5'GGCAGGAAGACAAACACACCATGTCTTGCGATGCGAAGGCCTTCTGCTCTCGCTTGTGGTCTGTGGTGCTGT3'
Sequence length: 72
GC content: 0.5555555555555556
Affinity: Kd: 129.2 ± 24.81 nM
Pool type: 5′-GGCAGGAAGACAAACA-N40-TGGTCTGTGGTGCTGT-3′
Pool random region: 40
Binding buffer/conditions: 50 ml of Dulbecco's phosphate-buffered saline (DPBS; Sigma, USA), 0.225 g of glucose, 250 μl of 1 M MgCl2, and 5 mg of yeast transfer RNA (tRNA; Invitrogen, USA)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Given the comparable specificity to their much more expensive antibody counterparts, these aptamers, when used in conjunction with the developed microfluidic system, may be used to diagnose ovarian cancer in its earliest stages. Automated, microfluidic, tissue-SELEX system developed herein is a promising tool for rapid screening cancer tissue-specific aptamers."
Reference (2019, Biomicrofluidics ): Liu, W. T., Lee, W. B., Tsai, Y. C., Chuang, Y. J., Hsu, K. F., & Lee, G. B. (2019). An automated microfluidic system for selection of aptamer probes against ovarian cancer tissues. Biomicrofluidics, 13(1), 014114. https://doi.org/10.1063/1.5085133
Aptamer: cTX-45
Target: Ovarian cancer tissues (OVCAR-3, National Cancer Institute #0507709, 104 cells per test)
Type of nucleic acid: ssDNA
Sequence: 5'GGCAGGAAGACAAACACGGGGCGCCATTGAACCGATCAAGGCGGTATGGTCAGGTGTGGTCTGTGGTGCTGT3'
Sequence length: 72
GC content: 0.5833333333333334
Affinity: Kd: 178.0 ± 43.5 nM
Pool type: 5′-GGCAGGAAGACAAACA-N40-TGGTCTGTGGTGCTGT-3′
Pool random region: 40
Binding buffer/conditions: 50 ml of Dulbecco's phosphate-buffered saline (DPBS; Sigma, USA), 0.225 g of glucose, 250 μl of 1 M MgCl2, and 5 mg of yeast transfer RNA (tRNA; Invitrogen, USA)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Given the comparable specificity to their much more expensive antibody counterparts, these aptamers, when used in conjunction with the developed microfluidic system, may be used to diagnose ovarian cancer in its earliest stages. Automated, microfluidic, tissue-SELEX system developed herein is a promising tool for rapid screening cancer tissue-specific aptamers."
Reference (2019, Biomicrofluidics ): Liu, W. T., Lee, W. B., Tsai, Y. C., Chuang, Y. J., Hsu, K. F., & Lee, G. B. (2019). An automated microfluidic system for selection of aptamer probes against ovarian cancer tissues. Biomicrofluidics, 13(1), 014114. https://doi.org/10.1063/1.5085133